BGI Genomics Co., Ltd. (300676.SZ)
CNY 48.27
(1.3%)
CNY 48.27
(1.3%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.6 Billion CNY | -13.08% |
| 2022 | 4.15 Billion CNY | -13.73% |
| 2021 | 4.81 Billion CNY | -6.9% |
| 2020 | 5.16 Billion CNY | 242.77% |
| 2019 | 1.5 Billion CNY | 50.95% |
| 2018 | 999.03 Million CNY | 17.0% |
| 2017 | 853.87 Million CNY | 9.82% |
| 2016 | 777.52 Million CNY | 4.88% |
| 2015 | 741.36 Million CNY | 27.08% |
| 2014 | 583.4 Million CNY | -35.14% |
| 2013 | 899.45 Million CNY | 5.41% |
| 2012 | 853.3 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.18 Billion CNY | -6.81% |
| 2024 Q1 | 3.41 Billion CNY | -5.42% |
| 2024 Q3 | 3.31 Billion CNY | 4.15% |
| 2023 Q2 | 3.53 Billion CNY | 2.63% |
| 2023 Q4 | 3.6 Billion CNY | 7.07% |
| 2023 FY | 3.6 Billion CNY | -13.08% |
| 2023 Q1 | 3.44 Billion CNY | -16.94% |
| 2023 Q3 | 3.37 Billion CNY | -4.77% |
| 2022 Q4 | 4.15 Billion CNY | 9.31% |
| 2022 Q3 | 3.79 Billion CNY | 6.09% |
| 2022 Q2 | 3.58 Billion CNY | -10.46% |
| 2022 FY | 4.15 Billion CNY | -13.73% |
| 2022 Q1 | 3.99 Billion CNY | -16.92% |
| 2021 Q1 | 4.88 Billion CNY | -5.55% |
| 2021 Q4 | 4.81 Billion CNY | -1.28% |
| 2021 Q3 | 4.87 Billion CNY | 6.46% |
| 2021 FY | 4.81 Billion CNY | -6.9% |
| 2021 Q2 | 4.57 Billion CNY | -6.21% |
| 2020 Q4 | 5.16 Billion CNY | 27.53% |
| 2020 FY | 5.16 Billion CNY | 242.77% |
| 2020 Q1 | 2.55 Billion CNY | 69.33% |
| 2020 Q2 | 4.36 Billion CNY | 71.05% |
| 2020 Q3 | 4.05 Billion CNY | -7.2% |
| 2019 Q4 | 1.5 Billion CNY | 40.32% |
| 2019 FY | 1.5 Billion CNY | 50.95% |
| 2019 Q3 | 1.07 Billion CNY | 1.76% |
| 2019 Q2 | 1.05 Billion CNY | 8.66% |
| 2019 Q1 | 971.9 Million CNY | -2.72% |
| 2018 Q4 | 999.03 Million CNY | 9.9% |
| 2018 Q1 | 718.41 Million CNY | -15.86% |
| 2018 Q2 | 895.56 Million CNY | 24.66% |
| 2018 FY | 999.03 Million CNY | 17.0% |
| 2018 Q3 | 909.06 Million CNY | 1.51% |
| 2017 FY | 853.87 Million CNY | 9.82% |
| 2017 Q3 | 820.99 Million CNY | 5.45% |
| 2017 Q1 | 725.25 Million CNY | -6.72% |
| 2017 Q2 | 778.59 Million CNY | 7.35% |
| 2017 Q4 | 853.87 Million CNY | 4.01% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 Q4 | 777.52 Million CNY | 0.0% |
| 2016 FY | 777.52 Million CNY | 4.88% |
| 2015 Q2 | 673.42 Million CNY | 6.86% |
| 2015 Q4 | 741.36 Million CNY | 0.0% |
| 2015 FY | 741.36 Million CNY | 27.08% |
| 2015 Q1 | 630.16 Million CNY | 0.0% |
| 2014 FY | 583.4 Million CNY | -35.14% |
| 2013 FY | 899.45 Million CNY | 5.41% |
| 2012 FY | 853.3 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 8.02 Billion CNY | 55.024% |
| Hangzhou Tigermed Consulting Co., Ltd. | 5.22 Billion CNY | 30.986% |
| Dirui Industrial Co.,Ltd. | 1.26 Billion CNY | -185.836% |
| Beijing Strong Biotechnologies, Inc. | 1.45 Billion CNY | -148.177% |
| Medicalsystem Biotechnology Co., Ltd. | 772.59 Million CNY | -367.126% |
| Maccura Biotechnology Co.Ltd | 1.5 Billion CNY | -139.357% |
| Guangzhou Wondfo Biotech Co.,Ltd | 1.15 Billion CNY | -211.901% |
| Guangdong Hybribio Biotech Co.,Ltd. | 615.23 Million CNY | -486.603% |
| Amoy Diagnostics Co., Ltd. | 221.04 Million CNY | -1532.703% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 1 Billion CNY | -258.498% |